COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,823 Articles (22,968 medRxiv, 8,855 bioRxiv)

Most recent first Previous |  Page 382: Articles 3811-3820  | Next

IFIH1 loss-of-function predisposes to inflammatory and SARS-CoV-2-related infectious diseases
Najm, R., Yavus, L., Jain, R., El Naofal, M., Ramaswamy, S., Abuhammour, W., Loney, T., Nowotny, N., Alsheikh-Ali, A., Abou Tayoun, A., Kandasamy, R.
10.1101/2023.10.13.23297034 — Posted: 2023-10-15
Surveillance and Stability of SARS-CoV-2 Wastewater Samples in Minnesota
Osborn, M., Champeau, S., Meyer, C., Hayden, M., Landini, L., Stark, S., Preeket, S., Vetter, S., Lynfield, R., Huff, D., Schacker, T., Doss, C. R.
10.1101/2023.10.14.23296666 — Posted: 2023-10-15
Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial
Zhang, B., Fong, Y., Fintzi, J., Chu, E., Janes, H. E., Carpp, L. N., Kenny, A., Carone, M., Benkeser, D., van der Laan, L. W. P., Deng, W., Zhou, H., Wang, X., Lu, Y., Yu, C., Borate, B., Houchens, C. R., Martins, K., Jayashankar, L., Huynh, C., Fichtenbaum, C. J., Kalams, S., Gay, C. L., Andrasik, M. P., Kublin, J. G., Corey, L., Neuzil, K. M., Priddy, F., Das, R., Girard, B., El Sahly, H. M., Baden, L. R., Donis, R. O., Koup, R. A., Gilbert, P. B., Follmann, D., United States Government (USG) COVID-19 Immune Assays Team, , Moderna, Inc. Team, , Coronavirus Vaccine Prevention Network (CoVP
10.1101/2023.10.15.23295628 — Posted: 2023-10-15
Resolving the pharmacological redox-sensitivity of SARS-CoV-2 PLpro in drug repurposing screening enabled identification of the competitive GRL-0617 binding site inhibitor CPI-169
Kuzikov, M., Morasso, S., Reinshagen, J., Wolf, M., Monaco, V., Cozzolino, F., Grdadolnik, S. G., Sket, P., Plavec, J., Iaconis, D., Summa, V., Esposito, F., Tramontano, E., Monti, M., Beccari, A. R., Windshugel, B., Gribbon, P., Storici, P., Zaliani, A.
10.1101/2023.10.11.561987 — Posted: 2023-10-15
Hidden evolutionary constraints dictate the retention of coronavirus accessory genes
Goldstein, S. A., Feeley, T. M., Babler, K. M., Hilbert, Z. A., Downhour, D. M., Moshiri, N., Elde, N. C.
10.1101/2023.10.12.561935 — Posted: 2023-10-14
Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein driving the genesis of Omicron variants
Yan, Q., Gao, X., Liu, B., Hou, R., He, P., Ma, Y., Zhang, Y., Zhang, Y., Li, Z., Chen, Q., Wang, J., Huang, X., Liang, H., Chen, X., Niu, X., He, J., Chen, L., Zhao, J., Xiong, X.
10.1101/2023.10.12.561995 — Posted: 2023-10-14
Nanobodies against SARS-CoV-2 non-structural protein Nsp9 inhibit viral replication by targeting innate immunity
Venit, T., Blavier, J., Maseko, S. B., Shu, S., Espada, L., Breunig, C., Holthoff, H.-P., Desbordes, S. C., Lohse, M., Esposito, G., Twizere, J.-C., Percipalle, P.
10.1101/2023.10.12.561992 — Posted: 2023-10-13
Akaluc bioluminescence offers superior sensitivity to track in vivo dynamics of SARS-CoV-2 infection
Tamura, T., Ito, H., Torii, S., Wang, L., Tsujino, S., Kamiyama, A., Oda, Y., Morioka, Y., Suzuki, S., Shirakawa, K., Sato, K., Yoshimatsu, K., Matsuura, Y., Iwano, S., Tanaka, S., Fukuhara, T.
10.1101/2023.10.12.561993 — Posted: 2023-10-13
A nationwide study of 331 rare diseases among 58 million individuals: prevalence, demographics, and COVID-19 outcomes
Thygesen, J. H., ZHANG, H., Issa, H., Wu, J., Hama, T., Pinho-Gomes, A.-C., Groza, T., Khalid, S., Lumbers, R., Hocaoglu, M., Khunti, K., Priedon, R., Banerjee, A., Pontikos, N., Tomlinson, C., Torralbo, A., Taylor, P., Sudlow, C., Denaxas, S., Hemingway, H., Wu, H.
10.1101/2023.10.12.23296948 — Posted: 2023-10-13
Mathematical modeling of SARS-CoV-2 variant substitutions in European countries: Transmission dynamics and epidemiological insights
Lopez de Rioja, V.
10.1101/2023.10.12.23296888 — Posted: 2023-10-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).